Condition
Severe Combined Immunodeficiency Due to ADA Deficiency
Total Trials
5
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Completed3
Unknown1
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04959890UnknownPrimary
Methodology Study of Retroviral Insertion Site Analysis in Strimvelis Gene Therapy
NCT03232203CompletedPrimary
Evaluating the Effectiveness of STRIMVELIS Risk Minimization Measures (RMMs)
NCT03765632Phase 1CompletedPrimary
Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCID
NCT04140539Phase 2WithdrawnPrimary
A Clinical Study to Enable Process Validation of Commercial Grade OTL-101
NCT02999984Phase 1CompletedPrimary
Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCID
Showing all 5 trials